Triple canine glaucoma therapy in one step. The New Generation for Glaucoma Treatment.
Glaucoma encompasses a group of ocular disorders characterized by elevated intraocular pressure (IOP), which can progressively impair vision if left unmanaged. Medical therapy aimed at reducing IOP is the recommended approach to delay onset and slow disease progression. However, in many canine patients, achieving and maintaining physiological IOP levels requires the use of multiple ocular hypotensive medications.
Three Proven Mechanisms. One Simplified Therapy.
Travosant Forte® integrates three complementary mechanisms of action into a single formulation:
This triple-combination therapy delivers robust IOP reduction, often achieving 20–30% greater pressure lowering from baseline.
We are excited to partner with Santgar, a a leading Mexican veterinary pharmaceutical innovator known for its commitment to research-driven, high-quality animal health solutions. Through this collaboration, we are bringing Travosant Forte to the U.S. market, expanding access to an advanced ophthalmic therapy for veterinary use.
This partnership combines Santgar’s scientific expertise with our focus on delivering trusted, effective medications that support better outcomes for veterinary patients.
Simplifying Complex Therapy While Delivering Maximal IOP Control.
This triple fixed-combination gel system helps minimize dilution or washout of active ingredients that can occur when multiple medications are administered in close
